RESEARCH ARTICLE

Nutraceutical-mediated restoration of wild-type levels of IKBKAP-encoded IKAP protein in familial dysautonomia-derived cells

Sylvia L. Anderson1, Bo Liu1, Jinsong Qiu1,2, Andrea J. Sturm1, Jamie A. Schwartz3, Austin J. Peters1, Kerry A. Sullivan1 and Berish Y. Rubin1

1Laboratory for Familial Dysautonomia Research, Department of Biological Sciences, Fordham University, Bronx, NY, USA
2Department of Cellular & Molecular Medicine, University of California (San Diego), La Jolla, CA, USA
3Department of Surgery, St. Luke’s-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY, USA

Scope: The reported ability to modulate the production of the wild-type transcript in cells bearing the splice-altering familial dysautonomia (FD)-causing mutation in the IKBKAP gene prompted an evaluation of the impact of commonly consumed nutraceuticals on the splicing of this transcript.

Methods and results: Screening efforts revealed the ability of the isoflavones, genistein, and daidzein, to impact splicing and increase the production of the wild-type, exon-20-containing transcript, and the full-length IKBKAP-encoded IKB kinase complex associated protein (IKAP) in FD-derived cells. Genistein was also found to impact splicing in neuronal cells, a cell type profoundly impacted by FD. The simultaneous exposure of FD-derived cells to genistein and epigallocatechin gallate (EGCG) resulted in the almost exclusive production of the exon-20-containing transcript and the production of wild-type amounts of IKAP protein.

Conclusion: This study represents the first demonstration that the isoflavones, genistein and daidzein, possess splice-altering capabilities and that simultaneous treatment with genistein and EGCG reverses the splice-altering impact of the FD-causing mutation. These findings support the clinical evaluation of the therapeutic impact of the combined administration of these two commonly consumed nutraceuticals on this patient population and suggest a broader evaluation of the impact of these nutraceuticals on the in vivo RNA splicing process.

Keywords: Alternative splicing / Familial dysautonomia / Genistein / Isoflavone / Nutraceutical

1 Introduction

Familial dysautonomia (FD) is an autosomal recessive disorder that impacts the development and survival of sensory, sympathetic, and some parasympathetic neurons [1, 2]. Individuals with FD exhibit decreased sensitivity to pain and temperature, cardiovascular instability, recurrent pneumonias, vomiting/dysautonomic crises, gastrointestinal dysfunction, and defective lacrimation [1–4]. FD is a life-threatening disorder with a high mortality rate. Two FD-causing mutations have been identified in individuals of Ashkenazi Jewish descent [5, 6]. The more common FD-causing mutation is a C→T transition in the sixth position of the 5′-splice donor site of intron 20 (termed as IVS20+6T→C) of the IKBKAP gene. This mutation alters the splicing process, resulting in the almost exclusive production of an exon-20-lacking transcript. Translation of this transcript produces a truncated nonfunctional protein.

The IKBKAP-encoded IKB (Ikappa B)-kinase-complex-associated protein (IKAP), initially named on the basis of
its reported ability to bind and serve as a scaffold protein for the IκB kinase complex [7], was subsequently found to not be associated with this complex [8, 9]. IKAP plays multiple cellular functions. It has been reported to be a subunit of the Elongator complex, where it plays a role in transcriptional elongation [10], and it has been demonstrated to be involved in regulation of the c-Jun N-terminal kinase (JNK) signaling pathway [11], exocytosis [12], neuronal development during embryogenesis [13], tRNA modification [14], and actin cytoskeleton regulation [15].

The observed production of a small, but detectable, amount of the exon-20-containing IKBKAP transcript in cell lines and tissues from individuals with FD [16] prompted a search for therapeutic modalities capable of facilitating the production of the exon-20-containing IKBKAP transcript in those affected. In 2003, we reported that the tocotrienols, members of the vitamin E family, elevate the production of the exon-20-containing transcript in FD-derived cells by increasing the rate of transcription of the IKBKAP gene [16]. Clinical analysis of the impact of the tocotrienol administration in individuals with FD revealed the tocotrienol-mediated elevated production of the full-length IKBKAP transcript in peripheral blood cells, improvement of cardiac function, a reduced incidence of dysautonomic crises, and increased eye moisture [4, 17–19, http://emedicine.medscape.com/article/1200921]. Additional screening efforts have demonstrated that epigallocatechin gallate (EGCG), a flavonoid present in plants, and a plant cytokinin, facilitate the inclusion of exon 20 in the transcript generated in FD-derived cell lines [20, 21].

Experiments examining the impact of the combined treatment of cells with EGCG and tocotrienols revealed the synergistic production of the exon-20-containing transcript and functional IKAP protein [20]. Recent studies have demonstrated that the treatment of FD-derived cells with phosphatidylserine elevates IKBKAP gene expression, resulting in the increased production of the full-length transcript from the IVS20+6T→C bearing allele [22].

The demonstrated therapeutic potential of EGCG and tocotrienols, two commonly consumed nutraceuticals, in individuals with FD encouraged us to develop a screening program to examine the impact of hundreds of commonly consumed plant or animal-derived compounds on the splicing of the IKBKAP-derived transcript in FD-derived cells. Our focus on nutraceuticals reflects the growing understanding of the biochemical and physiological impact of these food-based compounds that have known safety profiles.

Two of the compounds, genistein and the related daidzein, which are extensively studied plant-derived isoflavones found in soy, were found to modulate the splicing of the IKBKAP-derived transcript in FD-derived cells, producing an increased amount of the wild-type, exon-20-containing transcript. We further report that treatment of FD-derived cells with a combination of genistein and EGCG results in the production of cellular levels of the IKAP protein that are comparable to that present in normal cells.

2 Materials and methods

2.1 Cell lines and reagents

The GM04589 and GM04663 cell lines, homozygous for the IVS20+6T→C FD-causing mutation, and the GM02912 cell line, derived from a healthy individual, were obtained from the NIGMS Human Genetic Mutant Cell Repository (Camden, NJ, USA). The normal human FS4 fibroblast cell line was kindly provided by Dr. Jan Vilcek. The LA1-55n, BE(2)-C, and CB-JMN neuronal cell lines were kindly provided by Dr. Robert A. Ross. All cell lines were maintained at 37°C in 5% CO2 in Minimal Essential Medium (MEM) (fibroblast cell line) or Dulbecco’s Modified Eagle’s Medium (DMEM) (neuronal lines) containing 10% fetal bovine serum (FBS). The HEK293 cell line was purchased from the ATCC (Manassas, VA, USA). Purified genistein and EGCG were purchased from Calbiochem (La Jolla, CA, USA) and daidzein from Sigma-Aldrich (St. Louis, MO, USA).

2.2 RNA preparation and reverse transcriptase polymerase chain reaction (RT-PCR)

Total RNA was purified using RNeasy Plus Mini Kits (Qiagen) according to the manufacturer’s directions. A total of 25 ng of total RNA were amplified in 20 μL RT-PCR reactions using OneStep RT-PCR Kits (Qiagen, Valencia, CA, USA). One-step RT-PCR was carried out as follows: one cycle of 50°C × 30 min and 95°C × 15 min, followed by 42 cycles of 94°C × 20 s, 58–60°C × 30 s, and 72°C × 30 s, and then a final extension of 72°C × 2 min. PCR products were analyzed on 2% agarose gels. Primers, used at a concentration of 0.5 μM, are shown in Table 1. Quantitect SYBR Green RT-PCR Kits (Qiagen) were used for real-time RT-PCR (Quantitative RT-PCR (qRT-PCR)) analysis of the relative quantities of the exon-20-containing transcript (wild-type). ABI PRISM 7000 and 7500 Sequence Detection Systems (Applied Biosystems, Foster City, CA, USA), programmed as follows, were used to perform the real-time RT-PCR and analysis: 50°C × 30 min and 95°C × 15 min for one cycle, followed by 40 cycles of 94°C × 15 s, 57–60°C × 30 s, and 72°C × 30–34 s. Primers, used at a concentration of 0.5 μM, are shown in Table 1. Results obtained are in the form of threshold cycle, or C_threshold, which refers to the PCR cycle at which the fluorescence of the PCR is increased to a calculated level above background. A change of 1.0 in C_threshold, assuming 100% PCR efficiency, reflects a two-fold change in the starting amount of the RNA template that was amplified. To present relative amounts of PCR product obtained, results are expressed as “fold induction” of the wild-type exon-20-containing transcript in treated cells over that present in untreated cells. To control for the amount of RNA present in the samples, RT-PCR amplification of actin mRNA was performed and used to standardize the IKBKAP results.
Table 1. Oligonucleotide primers used

<table>
<thead>
<tr>
<th>Template</th>
<th>Application</th>
<th>Primer</th>
<th>Sequence (5’→3’)</th>
<th>Accession #/template Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>IKBKAP ex 19–21</td>
<td>Minigene construction Forward caccctacagggccgcctgag</td>
<td>NT_008470 40 827 187–40 827 167</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reverse ctagggttagatcataataacag</td>
<td>NT_008470 40 825 483–40 825 506</td>
<td></td>
</tr>
<tr>
<td>pcDNA-IKBKAP</td>
<td>Minigene RT-PCR</td>
<td>Forward ctggctagttaagcttggtacc</td>
<td>vector (pcDNA3.1) 892–913</td>
<td></td>
</tr>
<tr>
<td>IKBKAP ex 19–23</td>
<td>RT-PCR</td>
<td>Forward gcacgaactgtgcctca</td>
<td>NM_003640 2757–2738</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reverse tagatcgcagacaaga</td>
<td>NM_003640 2987–2969</td>
<td></td>
</tr>
<tr>
<td>IKBKAP Wild-type</td>
<td>qRT-PCR</td>
<td>Forward agtgcctcagagtgc</td>
<td>NM_003640 2671–2688</td>
<td></td>
</tr>
<tr>
<td>ACTB</td>
<td>qRT-PCR</td>
<td>Reverse ctggcgaagaaagctcgt</td>
<td>NM_001101 223–240</td>
<td></td>
</tr>
<tr>
<td>CLK1 ex 2–5</td>
<td>RT-PCR</td>
<td>Forward gtcctgatgctctcaaatcacc</td>
<td>NM_001101 470–453</td>
<td></td>
</tr>
<tr>
<td>IHPK2 ex 1–3</td>
<td>RT-PCR</td>
<td>Reverse ggtggccagaaacaatcaggg</td>
<td>NM_0011005910 69–88</td>
<td></td>
</tr>
</tbody>
</table>

2.3 Western blot analysis

Cells treated as described were washed twice with PBS and lysed in NuPAGE LDS sample buffer (Invitrogen, Carlsbad, CA, USA). Western blot analysis was performed essentially as described [23]. Equal amounts of protein fractionated on a 7% NuPAGE tris-acetate gel (Invitrogen) were blotted onto nitrocellulose (Bio-Rad, Hercules, CA, USA) and probed overnight with a monoclonal antibody raised against amino acids 796–1008 of IKAP (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The blots were then washed and probed with a goat antimouse antibody conjugated to alkaline phosphatase (Promega, Madison, WI, USA), followed by detection with Western Blue Substrate solution (Promega). The loading of equal amounts of protein was confirmed by Coomassie Blue staining of a 7% NuPAGE tris-acetate gel that was run in parallel. Quantification of bands on Westerns was accomplished by scanning the blots, then determining the densities of the bands using ImageJ software [24].

2.4 Construction of the FD mutation-bearing IKBKAP minigene (IKBKAP-FD) and the generation of HEK293 cells constitutively expressing the IKBKAP minigene

A fragment of DNA containing IKBKAP genomic sequence spanning exons 19 to 21 was generated from DNA derived from a cell line homozygous for the IVS20+6T→C FD-causing mutation, using PfuUltra II Fusion HS DNA polymerase (Stratagene, La Jolla, CA). Primers used are listed in Table 1. This DNA fragment was inserted into the pcDNA3.1/V5-His-Topo vector (Invitrogen) according to the manufacturer’s instructions. The resulting minigene was purified using a QiAprep Spin Miniprep Kit (Qiagen) and sequenced by Sanger dideoxy sequencing (Genewiz, Inc., South Plainfield, NJ, USA). HEK293 cells seeded for 24 h in a 75 cm² flask were transfected with 400 ng of the minigene construct in the presence of Lipofectamine 2000 (Invitrogen) in Opti-MEM-reduced serum medium (Invitrogen) according to the manufacturer’s directions. Six hours after transfection, the media was changed to fresh culture media containing 1 mg/mL G418. Surviving cells were isolated following a 4-week exposure to the G418 and the selected cells were maintained in media containing 1 mg/mL G418.

2.5 IKBKAP minigene splicing assay

HEK293 cells constitutively expressing the IKBKAP-FD minigene were seeded into wells 24 h before exposure to the compounds being studied. Following a 48 h incubation period, the cells were harvested and their RNA purified as described above. RT-PCR was performed as described above using primers (Table 1) that specifically amplified the minigene-derived IKBKAP exon-20-containing and exon-20-lacking transcript.

2.6 Analysis of IKBKAP-, CLK1-, and IHPK2-encoded RNAs in fibroblast and neuronal cells

Cells were seeded into 25 cm² flasks 1 week (fibroblast cell lines) or 24 h (neuronal cell lines) before treatment. Fibroblasts were confluent when treated and neuronal cells were approximately 25% confluent when treated. Following 48 h of treatment with 50 µg/mL genistein, cells were washed with PBS and total RNA was isolated as described above. Primers that spanned regions of alternative splicing in IKBKAP, CLK1, or IHPK2 transcripts were used to simultaneously amplify both transcript forms. RT-PCR products were analyzed on 2% agarose gels.

3 Results

3.1 Construction of IKBKAP-FD minigene for compound screening

To characterize the impact of large numbers of compounds on the splicing of the exon-20-encoded sequence of the
IKBKAP transcript produced by the allele bearing the FD-causing mutation, we generated an HEK293 cell line that contained and constitutively transcribed a minigene containing exons 19–21 of IKBKAP that carries the FD-causing IVS20+6T→C mutation was stably transfected into HEK293 cells. The diagram depicts the two IKBKAP-encoded transcripts constitutively expressed from the minigene: (i) the normal (wild-type), exon-20-containing, transcript in which introns 19 and 20 are spliced out and exon 20 is retained; and (ii) the aberrant, exon-20-lacking transcript, in which introns 19 and 20 as well as exon 20 are spliced out. (B) RNA purified from two FD-derived cell lines, GM04589 (FD1) and GM04663 (FD2), and from the minigene-containing HEK293 cell line was subjected to RT-PCR with primers spanning exons 19–23 (for the FD cell-line-derived RNA) or with a vector-specific primer and a primer in exon 21 (for the minigene-transfected HEK293 cell-line-derived RNA) of the IKBKAP transcript under conditions as described in Section 2. Primer sequences are listed in Table 1. RT-PCR products were separated on agarose gels with a typical experiment depicted. (C) RNA, isolated from minigene-transfected HEK293 cells incubated in the absence (unt) or presence (G) of 50 μg/mL genistein for 48 h, was purified and subjected to RT-PCR as described above.

**Figure 1.** An FD minigene construct expressing normal and aberrant IKBKAP RNA splice variants expresses more normal transcript in response to genistein. (A) A pcDNA3.1/v5-His-TOPO vector construct containing a genomic DNA fragment encoding exons 19–21 of IKBKAP that contains the FD-causing IVS20+6T→C mutation was stably transfected into HEK293 cells. The diagram depicts the two IKBKAP-encoded transcripts constitutively expressed from the minigene: (i) the normal (wild-type), exon-20-containing, transcript in which introns 19 and 20 are spliced out and exon 20 is retained; and (ii) the aberrant, exon-20-lacking transcript, in which introns 19 and 20 as well as exon 20 are spliced out. (B) RNA purified from two FD-derived cell lines, GM04589 (FD1) and GM04663 (FD2), and from the minigene-containing HEK293 cell line was subjected to RT-PCR with primers spanning exons 19–23 (for the FD cell-line-derived RNA) or with a vector-specific primer and a primer in exon 21 (for the minigene-transfected HEK293 cell-line-derived RNA) of the IKBKAP transcript under conditions as described in Section 2. Primer sequences are listed in Table 1. RT-PCR products were separated on agarose gels with a typical experiment depicted. (C) RNA, isolated from minigene-transfected HEK293 cells incubated in the absence (unt) or presence (G) of 50 μg/mL genistein for 48 h, was purified and subjected to RT-PCR as described above.

IKBKAP transcript produced by the allele bearing the FD-causing mutation, we generated an HEK293 cell line that contained and constitutively transcribed a minigene containing genomic DNA spanning exons 19–21 of the FD mutation-bearing IKBKAP allele (Fig. 1A). Using primers designed to amplify the vector-derived transcript, we observed that, like the IKBKAP-derived transcript produced in FD-derived cells, both an exon-20-containing (normal, i.e., wild-type) and an exon-20-lacking (aberrant) transcripts are produced by this minigene (Fig. 1B). As is the case in the FD-derived fibroblasts, the majority of the minigene-expressed IKBKAP transcripts lack exon 20.

**3.2 Genistein impacts splicing of IKBKAP transcripts**

The screening of several hundred extracts of commonly consumed compounds in extract or purified form revealed the ability of the isoflavone genistein to enhance the production of the exon-20-containing transcript from the IKBKAP-FD minigene (Fig. 1C). To characterize the effect of genistein on the IKBKAP transcript produced in FD-derived cell lines, two FD-derived fibroblast cell lines were incubated in the presence or absence of 50 μg/mL of genistein and the IKBKAP transcripts generated in these cells were characterized by RT-PCR, using primers recognizing exon 19 and 23 sequences that amplify both the exon-20-containing and the exon-20-lacking transcripts (Fig. 2A). Genistein not only increased the expression of the exon-20-containing transcript, but clearly changed the exon-20-containing: exon-20-lacking transcript ratio.

qRT-PCR was performed using primers that amplify only the exon-20-containing transcript (Fig. 2B). qRT-PCR analysis revealed an approximately two-fold increase in the level of exon-20-containing transcript produced in the genistein-treated cells as compared to untreated cells. Treatment of the FD-derived fibroblast cell lines with the related isoflavone daidzein similarly elevated the level of exon-20-containing transcript produced in the FD-derived cell lines (Fig. 2C).

**3.3 Genistein increases IKAP protein levels in FD-derived cells**

To determine whether the genistein-mediated increased production of the exon-20-containing transcript impacts the level of the full-length IKAP protein, Western blot analysis was performed on FD-derived cell lines incubated in the absence or presence of genistein (Fig. 3A and B). A clear elevation of the full-length protein was detected in the genistein-treated cells.

**3.4 Genistein impacts splicing of CLK1 and IHPK2 RNA in neuronal cells**

As FD is a disorder that impacts the development and survival of sensory, sympathetic, and parasympathetic neurons, and as mRNA splicing has been demonstrated to be differentially regulated in different cell types, the observed impact of genistein on the splicing of the IKBKAP transcript in FD-derived fibroblast cell lines might not accurately reflect the impact of this compound on the splicing process occurring in neuronal cells. To study the impact of genistein on RNA splicing in neuronally derived cell lines, we first selected 30 genes from the kinase list on the Exonhit Therapeutics (Gaithersburg, MD) splicearray portal (http://portal.splicearray.com/PortalHome/) and designed primers to amplify the RNA resulting from alternate splicing events previously reported to occur in the processing of these gene transcripts. We assayed for the impact of genistein on these events by performing RT-PCR on RNA isolated from untreated and genistein treated FD-derived fibroblast cells and observed that genistein modulated two
of these splicing events. It mediated the inclusion of exon-4-encoded sequence in the CDC-like kinase 1 (CLK1)-encoded transcript and the inclusion of a novel 131 bp exon between exons 2 and 3 in the inositol hexaphosphate kinase 2 (IHPK2)-encoded transcript in the FD-derived fibroblast cells (Fig. 4A).

We then examined the impact of genistein treatment on the CLK1- and IHPK2-encoded transcripts in several neuronally derived cell lines and observed that the splice-modulating activity of genistein occurs in cells of neuronal origin (Fig. 4B).

3.5 Combined treatment with EGCG and genistein synergistically upregulates wild-type IKBKAP-encoded RNA and protein levels

The reported ability of EGCG to modulate the splicing process and facilitate the inclusion of exon 20 in the transcript generated from the IVS20+6T→C-bearing IKBKAP allele [20] prompted an examination of the response of FD-derived cells to the combined treatment of genistein and EGCG. For this study, cells were treated in either the absence or the presence of EGCG, genistein, or a combination of these compounds and the impact on the splicing of exon 20 was examined by RT-PCR. The combined treatment of EGCG and genistein resulted in a synergistic increase in the relative amount of the exon-20-containing RNA generated in these cells (Fig. 5A). To quantify the impact of these treatments on the IKBKAP transcript, qRT-PCR was performed on the RNA isolated from these cells and the relative amounts of IKBKAP exon-20-containing (wild-type) transcripts were determined. As reported here and previously [20], treatment with genistein or EGCG elevates the level of the exon-20-containing transcript present in FD-derived fibroblasts. The combined treatment with these two compounds resulted in an approximately five-fold increase in the amount of wild-type transcript produced in these cells (Fig. 5B).
Figure 4. CLK1 and IHPK2 transcripts are alternatively spliced in FD-derived and neuronal cell lines treated with genistein. (A) RNA was isolated from two FD-derived cell lines, GM04589 (FD1) and GM04663 (FD2), incubated for 48 h in the absence (unt) or presence (G) of 50 μg/mL genistein and subjected to RT-PCR as described in Section 2. Primers used to amplify regions of alternative splicing in CLK1 and IHPK2 transcripts are listed in Table 1. RT-PCR products were separated on agarose gels with a typical experiment depicted. (B) RNA was isolated from three neuronally derived cell lines, CB-JMN, Be(2)-C, and LA1-55n, that were incubated for 48 h in the absence (unt) or presence (G) of 50 μg/mL genistein and the CLK1 and IHPK2 transcripts were analyzed as described above. (C) The schematic depicts alternatively spliced transcripts visualized on the agarose gels shown in “A” and “B” of this figure. The larger CLK1 transcript contains exon 4, while in the smaller one, exon 4 is spliced out. The larger IHPK2 transcript contains an alternative exon 2a that is not present in the smaller band.

EGCG and genistein prompted an analysis of the impact of these treatments on the level of IKAP protein present in these cells. Western blot analysis revealed a synergistic increase in the level of full-length IKAP protein present in the cells treated with the combination of EGCG and genistein, and the amount of protein present in these cells is comparable to that observed in fibroblast cells derived from normal individuals (Fig. 6).

4 Discussion

The accurate removal of introns from pre-mRNA is a complex process that is regulated by cis-acting sequences and trans-acting factors. The cis sequences include donor and acceptor splice sites, intronic branch points, intronic polypyrimidine tracts, and auxiliary elements known as exonic and intronic splicing enhancers (ESEs and ISEs, respectively) and exonic
and intronic splicing silencers (ESSs and ISSs, respectively) [25, 26]. Cis elements recruit specific RNA binding proteins that either enhance or repress the use of the adjacent splice sites. The relative levels of the splicing factors during development and in different tissues regulate the splicing process and enable the generation of multiple proteins isoforms from a single pre-mRNA transcript. A survey of alternative pre-mRNA splicing events predicts that at least 74% of human genes undergo alternative splicing [27].

Disruption of exon recognition and misregulation of splicing are common causes of human disease. Estimations of the percentage of disease-causing mutations that affect the splicing process range from 15% [28] to 62% [29]. A recent study of possible splice-regulating sequence motifs suggests that 22% of known disease-causing missense mutations may mediate their deleterious effects as a result of their impact on the RNA splicing process [30]. The significant role that dysregulation of splicing plays in human diseases has encouraged the development of therapeutic approaches that target and modulate the RNA splicing machinery.

Since the identification of the genetic cause of FD and the demonstration that this disorder is almost exclusively caused by a mutation that alters the splicing process, causing the skipping of the exon-20-encoded sequence of the IKBKAP gene, much research has focused on the development of therapeutic approaches that facilitate the production of the correctly spliced transcript. To date, treatment of FD-derived cells with two compounds, EGCG and kinetin, has been demonstrated to alter the splicing process and facilitate the inclusion of exon 20 in the IKBKAP transcript [20, 21]. As EGCG is present in commonly consumed foods, in particular, green tea, its use by the FD patient population was unimpeded and without adverse side effects. Improvement of neurological function has been recorded in individuals with FD who have ingested 700 mg of EGCG daily (Rubin et al., unpublished data). A recent study evaluating the impact of kinetin in individuals with FD has revealed that it effectively increases the production of the wild-type transcript in peripheral blood cells of these patients [31], but its use may be limited because its administration has been demonstrated to cause liver toxicity and nausea in many of the participants in this study [31].

The previous identification of commonly consumed compounds that facilitate the production of the wild-type IKBKAP transcript in cells derived from individuals with FD [16, 20] encouraged us to evaluate the impact of several hundred compounds, including genistein, on the production of the wild-type transcript. Genistein, a compound found in soy, has been previously reported to have protein tyrosine kinase inhibitor activity [32, 33] and neuro- and cardio-protective properties [34–42]. It may also play a therapeutic role in the treatment of cystic fibrosis (CF) through its effect on Cl− gating and cystic fibrosis transmembrane conductance regulator (CFTR) maturation/localization [43, 44] and mucopolysaccharidoses (MPSs) by impairing glycosaminoglycan production [45]. In this study, we report for the first time the ability of genistein to alter the splicing process and facilitate the inclusion of exon 20 in the IKBKAP-encoded transcript produced in fibroblast cell lines derived from individuals with FD. As FD is a disorder that primarily impacts neuronal cells, and as the splicing process has been demonstrated to be differentially regulated in different cell types, we characterized the impact of genistein on the splicing of mRNAs present in neuronally derived cells. We observed that genistein treatment modulates the splicing process and facilitates increased exon inclusion in the CLK1- and IHPK2-encoded transcripts in these cells.

Characterization of the impact of genistein on more than 100 known alternative splicing events demonstrated that it modulates only a small percentage of these events.
Genistein’s impact on the RNA splicing process reveals a newly identified mechanism by which it can modulate gene expression. As protein phosphorylation plays a critical role in the activity and cellular location of proteins involved in the regulation of RNA splicing [46], and as changes in splice site selection have been observed when the activity of kinases or phosphatases is manipulated [47, 48], it is possible that genistein is modulating the splicing process through its reported ability to act as a protein tyrosine kinase inhibitor [32, 33].

We report that the combined treatment of EGCG and genistein results in the almost exclusive production of the exon-20-containing transcript in FD-derived cells and the production of IKAP protein levels comparable to that found in normal human fibroblasts. As the FD-causing mutation impacts the structure and function of both the central and peripheral nervous system, the ability of both EGCG and genistein to cross the blood-brain barrier [49, 50] suggests that their use, individually and in combination, may benefit those with FD. Clinical studies to evaluate their combined efficacy are currently being designed.

The impact of pharmaceuticals and nutraceuticals on splicing events involved in genetic diseases has extensively been investigated in many laboratories. Much of this effort has focused on the development of therapeutic modalities to treat spinal muscular atrophy (SMA). SMA is a neurodegenerative disorder that results from homozygous deletions or mutations of part or all of the survival of motor neuron gene-1 (SMN1) [51]. The SMN2 gene, which is retained in individuals with SMA, is nearly identical to the SMN1 gene but contains a C→T base change at position +6 in exon 7 which facilitates alternative splicing and a low efficiency of exon 7 inclusion in the SMN2 transcript [52, 53]. The exon-7-deficient SMN2-derived transcript generates a protein that is defective in self-oligomerization and is unstable [54]. Using cells derived from individuals with SMA, Lorson and coworkers examined the effect of polyphenolic botanical compounds on mRNA splicing and reported that treatment with EGCG resulted in an approximately 40% increase in the amount of total protein generated from the SMN2 allele in SMA-derived cells [55]. This finding prompted us to investigate the impact of the combination of EGCG and genistein on the SMN2-derived transcript. We have observed that both EGCG and genistein individually increase the amount of exon-7-containing SMN2 transcript produced in the SMA-derived fibroblast cells and that the combined treatment with these two nutraceuticals results in the exclusive production of the exon-7-containing SMN2 transcript (Anderson et al., manuscript in preparation). This observation suggests the therapeutic potential for this combination of nutraceuticals in the treatment of SMA.

Our findings suggest that diet may influence the phenotype observed in individuals with identical splice-altering mutations. A very dramatic difference in the phenotype of individuals from two distinct populations that are homozygous for the same splice-altering IVS4+6A→T mutation of the fanconi anemia gene, FANCC, has been reported by Futaki and coworkers [56]. Individuals of Ashkenazi Jewish descent homozygous for this mutation exhibit severe symptoms that are usually detected at birth. In contrast, individuals of Japanese descent who are homozygous for this same mutation show much milder symptoms that appear later in life. It has been suggested that environmental factors or other genes may modulate the phenotype associated with this mutation [56]. It is interesting to consider that the Japanese diet, which includes large amounts of soy, rich in genistein and daidzein, and green tea, which is high in EGCG, may provide the environmental basis for modulation of the splicing process and production of the correctly spliced transcript from the IVS4+6A→T-bearing FANCC gene.

Our findings that the ingestion of tocotrienols, a compound present in brown rice, facilitates the production of the full-length IKBKAP gene product [16] and mitigates some of the symptoms observed in individuals with FD [4, 18, 19, http://emedicine.medscape.com/article/1200921], clearly demonstrates the ability of food-derived compounds to impact the in vivo expression and manifestations of a splice-altering mutation. An environmental impact on the production of the functional gene product from the IVS20+6T→C-bearing IKBKAP allele is not limited to compounds found in foods. In 2005, Axelrod and coworkers reported that fludrocortisone, a synthetic corticosteroid that has been used to treat postural hypotension in patients with FD, alters the splicing process and reduces the production of the exon-20-containing IKBKAP transcript in cells derived from patients with FD [57]. This observation, taken together with our findings, supports the continued analysis of the effects of nutraceuticals and pharmaceuticals on the inclusion and exclusion of exon 20 sequence in the IKBKAP transcript produced in FD-derived cells.

We thank Dr. Robert Ross for his critical reading of the manuscript and his insightful comments. This work was funded by grants from Familial Dysautonomia Now, the Cure FD Foundation, and the Eric Alterman Foundation for F.D. Cure. We also acknowledge the generous support of NYC Council Member G. Oliver Koppell and his securing of funds from the New York City Council to support this research effort.

The authors have declared no conflict of interest.

5 References


© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.mnf-journal.com


